US Stock MarketDetailed Quotes
HUMA Humacyte
- 4.280
- -0.210-4.68%
Close Nov 25 16:00 ET
- 4.240
- -0.040-0.93%
Pre 05:02 ET
550.70MMarket Cap-3194P/E (TTM)
4.640High4.220Low3.65MVolume4.470Open4.490Pre Close15.83MTurnover3.82%Turnover RatioLossP/E (Static)128.67MShares9.97052wk High-8.65P/B409.22MFloat Cap2.45152wk Low--Dividend TTM95.61MShs Float17.450Historical High--Div YieldTTM9.35%Amplitude1.960Historical Low4.339Avg Price1Lot Size
Humacyte Stock Forum
Sign in to post a comment
$Humacyte (HUMA.US)$
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.
1
2
NOTE: NFA. Do not open position without buy pressure, volume. Check indicators, chart.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
54
8
$Humacyte (HUMA.US)$ Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024
Benzinga· 3 mins ago
Benzinga· 3 mins ago
1
$Humacyte (HUMA.US)$
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
1
$Humacyte (HUMA.US)$ shd i sell this shit stock ?
2
$Humacyte (HUMA.US)$ Humacyte Presents Preclinical Results Of Small-Diameter ATEV For Coronary Artery Bypass Grafting At American Heart Association's Scientific Sessions 2024; SdATEV Was Observed To Recellularize With Host Cells And Remodel To Effectively Reduce The Initial Size Mismatch Between The SdATEV And The Animal's Native Artery
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
2
$Humacyte (HUMA.US)$
what happened? the earnings suck but now the stock is rising
what happened? the earnings suck but now the stock is rising
1
$Humacyte (HUMA.US)$ Look at the price target from two days ago..$25..
Do you think that is a credibility issue maybe they raise this company some money along the way and they need to be bullish to get potential business from them in the future.
Do you think that is a credibility issue maybe they raise this company some money along the way and they need to be bullish to get potential business from them in the future.
1
5
unbelievable , looking at success rate and returns my success rate and return is little bit higher around above breakeven current year 
$Humacyte (HUMA.US)$
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Humacyte (HUMA) presented positive Phase 3 clinical trial results for their ATEV (acellular tissue engineered vessel) in arteriovenous access for hemodialysis patients. The trial demonstrated superior performance compared to standard autogenous fistula, with 81.3% functional patency at 6 months versus 66.4%, and 68.3% seco...
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Humacyte (HUMA) presented positive Phase 3 clinical trial results for their ATEV (acellular tissue engineered vessel) in arteriovenous access for hemodialysis patients. The trial demonstrated superior performance compared to standard autogenous fistula, with 81.3% functional patency at 6 months versus 66.4%, and 68.3% seco...
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
104983812 : No news about the results?
102875548 OP 104983812 : Ya... no news at all...